Coherus Oncology: The Catalyst Rich Period Is Here

Coherus Oncology enters a catalyst-rich period with multiple clinical readouts for tagmokitug and casdozokitug in H2'26 and H1'27. Prior anti-CCR8 clinical evidence supports potential efficacy in select indications, including in colorectal and gastric cancers, enhancing CHRS's upside prospects. Loqtorzi revenues are projected to grow, but Q2'26 results and future capital raises remain key risks to monitor. CHRS's toripalimab is also in trials being run by other companies, providing additional potential readouts in the future.

Coherus Oncology (CHRS) has not experienced a sustained run-up, despite the fact the company is approaching a catalyst-rich period. Given CHRS had five or more clinical readouts possible in 2026 and Loqtorzi (toripalimab) was performing